programmed cell death ligand 1

You have access
Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats
Alizée Bouleau, Hervé Nozach, Steven Dubois, Dimitri Kereselidze, Céline Chevaleyre, Cheng-I Wang, Michael J. Evans, Vincent Lebon, Bernard Maillère and Charles Truillet

Journal of Nuclear Medicine August 1, 2022, 63 (8) 1259-1265; DOI: https://doi.org/10.2967/jnumed.121.262967
You have access
Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer ¹⁸F-BMS-986192
Thijs S. Stutvoet, Elly L. van der Veen, Arjan Kol, Inês F. Antunes, Erik F.J. de Vries, Geke A.P. Hospers, Elisabeth G.E. de Vries, Steven de Jong and Marjolijn N. Lub-de Hooge

Journal of Nuclear Medicine December 1, 2020, 61 (12) 1839-1844; DOI: https://doi.org/10.2967/jnumed.119.241364

Main menu